The ovarian cancer risk was estimated at 35–46% in BRCA1 carriers and 13–23% in BRCA2 carriers.4 Other studies have estimated these risks to be even higher.5 Given these risks, targeting BRCA pathogenic mutations in breast cancer patients is an attractive strategy for systemic therapy. This evidence concerns the gene BRCA2 and breast carcinoma.